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Abstract 
Observed the patient with prostate cancer during five years to measure the survival rate that for 
evaluating the effectiveness of diagnosis and treatment options. 
This study conducted to study bone scan and PSA level and their relation to prostatic 
Malignancy among Sudanese. 
This study is a retrospective cohort study, which was performed in Sudan. The sample magnitude 
was 306 prostate carcinoma patients with age ranged between 43-93 years. The patients' follow-
up through 5 years studied in order to assess whether of them were alive or dead. The observed, 
corrected and expected five survival of the population were used. Kalban-Meier calculation 
methods of five years survival were used. 
The study found that only 111 (36.3%) of the 306 patients animated 5 years afterward their dates 
of initial management and therefore, the 5 years survival rate is 37%. The study found that the 
survival rate were 37%, 42% and 44% (p > 0.05) respectively. 
The study found that there were many factors affected the survival rate in Sudanese population 
such as treatment type and diagnosis date. 
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1. Introduction 
 
In the Introduction section, present clearly and briefly the problem investigated, with relevant 
references. 
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Cancer is type of disorders that branded by out of body regulator growing and antagonistic 
behavior. It has more than 150 types and they alienated according to their origin. It causes the 
harm to the body when the affected cells divide irrepressibly to produce multitudes of tissue 
termed tumors excepting in certain types. Tumors can rapidly proliferate and amend the 
functions of various body systems due to their secreted hormones. Tumors, which remain in one 
place and are generally considered benign. The benign tumors rest in same site and establish 
restricted growing rather than the malignant ones. The malignant tumors tend to brand new blood 
supply to nourish in a procedure named angiogenesis.  Prostate cancer considers one of the 
furthermost tumor in world; it classify second among all cancers in both genders after breast in 
2012
1
. It likewise the most common type among the Sudanese males
2
. In people with prostate 
cancer, the bone is usually the primary distant place of metastasis. More than two-third of 
secondary prostate carcinomas metastasize to the bones
3
. Survival ratio is an amount of existence 
fraction of cancer patients. It is the amount of persons who survive after a certain period after the 
diagnosis of the disease. Survival rates are crucial for treatment efficiency study. It depends on 
the entire inhabitants. Discrete prognosis is contingent on novel managements. Since the 
previous numerical analysis as well as the patient health condition
4
.  The survival rate divides 
into many types depends on the time such as five years and ten years. It computes form the 
diagnosis date5.  One of survival rate for assess the prognosis of disorder, generally calculated 
diagnosis period. The five years survival is defined as the number of patients who lived for 5 
years from the tumor detection date. It used to assess the efficiency of management
6
. 
 
2. Materials and Methods  
 
This study was a retrospective cohort study, which was performed in amongst the cancer patients 
in Sudan. The sample magnitude was 306 patients with prostate cancer. The patients’ age ranged 
between 45-95 years old. The study data was retrieved from patients' files system of Radiation 
and Isotopes Center of Khartoum (RICK) which included patient age, occupation, symptoms and 
its intervals, site of tumor and its magnitude, number of patient in year after diagnosis, number of 
alive at beginning of year, number of dying patient during year, Number of patients last seen 
alive during year. The 5-years survival rate, direct method, actuarial method and Kalban-Meier 
method calculation used in this study. 
 
 
3. Results and Discussions  
 
Calculation by the Direct Method 
 
111 patients of total number of 306 patients were lived for 5 years. The total 5-years survival rate 
of was 36.3 % of all patients after estimated by the direct measurement technique.  
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Table 1: Calculation of observed survival rate, and its standard error, by the actuarial (life-table) 
method 
(10) 
Entry(6) 
Divided 
By 
entry 
(9) 
( qi ) 
ـــــــــــــــــ 
ri - di 
(9) 
Entry 
(5) 
Minus 
Entry 
(3) 
 
 
(ri – di ) 
(8) 
Proportion 
Surviving 
From list 
Treatment 
to end year 
(11pi) 
(7) 
Proporti
on 
Survivin
g 
year 
(pi) 
(6) 
Proportion 
Dying 
During 
Year 
(qi) 
(5) 
Effective 
No. 
Exposed 
to 
Risk of 
Dying 
(ri) 
(4) 
No. 
last 
seen 
Alive 
Durin
g 
Year 
(wi) 
(3) 
No 
Dying 
During 
year 
(di ) 
(2) 
No. alive 
at 
Beginning 
of Year 
(li ) 
(1) 
Year 
after   
Diagnosis 
(i) 
0.0000 298 0.974 0.974 0.026 306.0 0 8 306 0 
0.2450 224.5 0.735 0.755 0.245 297.5 1 73 298 1 
0.0013 173 0.570 0.776 0.224 223.0 2 50 224 2 
0.0013 140 0.467 0.819 0.181 171.0 2 31 172 3 
0.0014 115.5 0.389 0.834 0.166 138.5 3 23 139 4 
- -  - - - 113 - 113 ≥ 5 
0.249      121 185  Total 
(ri)=li -  
𝑤𝑖
2
                                   qi=
𝑑𝑖  
𝑟𝑖
                                      pi = 1-qi 
 
Calculation by the Actuarial Method (Life Table) 
 
The five-year survival rate measured by the life-table technique is 0.389 or 39%. The life-table 
method was dependable since it was founded on more data. One benefit of the life-table 
technique is that it offers data about vicissitudes in the risk of dying in successive intervals of 
observation.  
 
Thus, column 6 (qi) shows that the amount of patients dying in each of the first 4 years after 
diagnosis augmented from 3% in the first year to 19% in the fourth. The increasing rates in 
column 8 may be used to plot a survival curve, providing a pictorial description of the survival 
pattern (Figure 1). 
 
Table 2: Calculation of the corrected survival rate 
(8) 
Proportio
n 
Surviving 
From list 
Treatment 
to end 
year 
(11pi) 
(7) 
Prop
ortio
n 
Survi
ving 
year 
 
 
(pi) 
(6) 
Proportion 
Dying 
During 
Year 
 
(qi) 
(5) 
Effectiv
e No. 
Expose
d to 
Risk of 
Dying 
 
(ri) 
(4) 
No. last 
seen 
Alive 
During 
Year 
(wi) 
(3) 
No Dying 
During 
year 
(di ) 
(2) 
No. alive at 
Beginning of 
Year 
 
 
(li ) 
(1) 
Year 
after   
Diagnosis 
 
 
(i) 
 
 
 
(b) 
From 
other 
causes 
(d(o)i 
(a) From 
Cancer 
 
(d(c)i 
 
 
0.980 0.980 0.020 305.0 0 2 6 306 0 
0.751 0.766 0.234 295.5 1 4 69 298 1 
0.595 0.792 0.208 221.0 2 4 46 224 2 
0.496 0.834 0.166 168.5 2 3 28 172 3 
0.420 0.846 0.154 136.5 3 2 21 139 4 
 - - - 113  - 113 ≥ 5 
    121 185   Total 
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Where       (𝑟𝑖) = 𝑙𝑖 − 
𝑤𝑖 + (𝑑(𝑜)𝑖   
2
                         𝑞𝑖 = (𝑑(𝑜)𝑖
𝑟𝑖
    𝑝𝑖 =  1 −  𝑞𝑖 
 
The five-year corrected survival rate is 42%, compared to an observed rate of 39%. The 
corrected rate indicates that 42% of patients with Prostate Cancer escaped the risk of death from 
the disease within 5 years of diagnosis. 
 
Table 3: Calculation of the relative cumulative survival rates among Prostate Cancer patients 
Based on data in Tables 1 
(9) 
Relative 
survival 
rate 
 
 
(11pi /ER) 
(8) 
Proportion 
Surviving 
From list 
Treatment 
to end 
year 
(11pi) 
(7) 
Proportion 
Surviving 
year 
 
 
(pi) 
(6) 
Proportion 
Dying 
During 
Year 
 
(qi) 
(5) 
Effective 
No. 
Exposed to 
Risk of 
Dying 
(ri) 
(4) 
No. last 
seen 
Alive 
During 
Year 
(wi) 
(3) 
No Dying 
During 
year 
 
 
(di ) 
(2) 
No. alive 
at 
Beginning 
of Year 
 
 
(li ) 
(1) 
Year 
after 
Diagnosis 
 
 
(i) 
0.974 0.974 0.974 0.026 306.0 0 8 306 0 
0.835 0.735 0.755 0.245 297.5 1 73 298 1 
0.647 0.570 0.776 0.224 223.0 2 50 224 2 
0.530 0.467 0.819 0.181 171.0 2 31 172 3 
0.442 0.389 0.834 0.166 138.5 3 23 139 4 
-  - - - 113 - 113 ≥ 5 
     121 185  Total 
(𝑟𝑖) = 𝑙𝑖 −  
𝑤𝑖  
2
                                  𝑞𝑖 =
𝑑𝑖
𝑟𝑖
                                        𝑝𝑖 = 1 − 𝑞𝑖                     
ER= Expected Survival Rate (0.88) 
Relative survival rate = 
(Observed survival rate)
Expected survival rate
𝑥 100% 
 
     Relative survival rate =
0.39
0.88
∗ 100% =  44 % 
 
Table 4:  Observed, corrected and relative cumulative survival rates among Prostate Cancer 
patients 
Years 
After diagnosis 
Observed 
survival rates 
Corrected 
survival rates 
relative survival 
rates 
0 0.974 0.980 0.974 
1 0.735 0.751 0.835 
2 0.570 0.595 0.647 
3 0.467 0.496 0.530 
4 0.389 0.420 0.442 
≥ 5    
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Figure 1: Observed, corrected and relative cumulative survival rates among Prostate Cancer 
patients Based on data in Tables 1 and 2 and 3. 
 
4. Conclusions & Recommendations  
 
The 5-years survival rate was 91.6% for patients who diagnosed in grade 1 of the disease, 76.5% 
in grade 2, 24%in grade 3 and 7.5% in grade 4. For all study samples, no one diagnosed in grade 
0. From all patients who treated  within the first month after the diagnose there are 68% survived 
more than 5 years, 36.5% for those who treated within the second month,29.3% for the third 
month,19% for the forth , 12.5% for the fifth month and 7% for patients who treated after more 
than 5 months from their diagnose. The best treatment given was the combination between 
surgery and radiotherapy which used for 21.2% of patients and resulted in 61.7% 5-years 
survival rate, followed by radiotherapy, chemotherapy, radiotherapy and chemotherapy, surgery 
and chemotherapy, and surgery+ radiotherapy+ chemotherapy .these protocols used for 
31.9,13.1, 24.3 ,2.5 and 1.9 % of all patients respectively and resulted in 21% ,6%, 6%, 0% and 
0% 5-years survival rates respectively. Patients of the age group of 20-30 years were 11.2% from 
all patients and their 5-years  survival rate was 50%, 31-40 years group was 15.6% from all 
patients and survived by 48%,41-50 years group was 21.8% of all patients and survived by 
34.3%,   age group of 51-60 was 25% from all patients and there are 30% survived from this 
group, 61-70 years group was 20% and survived by 21.8% , the group of 71-80 years was 5% 
from all patients and there were 25% survived and the age group of 81-90 years was 1.8% from 
all patients and survival rate in this group was 0%. The observed, corrected and relative 5-years 
survival rate of cancer in Sudan are 40.5%, 52% and 47% respectively. The study found that the 
survival rate of prostate were 37%, 42% and 44% (p > 0.05) respectively.   
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